Opus Genetics (NASDAQ:IRD) Cut to Strong Sell at Zacks Research

Posted by Francis Steltz on Jul 15th, 2026

Opus Genetics (NASDAQ:IRD – Get Free Report) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.

Several other equities analysts have also issued reports on IRD. BTIG Research reissued a “buy” rating and set a $12.00 target price on shares of Opus Genetics in a research note on Monday, July 6th. B. Riley Financial reiterated a “buy” rating on shares of Opus Genetics in a research note on Thursday, April 30th. Cantor Fitzgerald initiated coverage on shares of Opus Genetics in a research note on Monday, March 30th. They issued an “overweight” rating and a $15.00 price objective for the company. Citizens Jmp restated a “market outperform” rating and issued a $11.00 price objective on shares of Opus Genetics in a report on Monday, June 15th. Finally, Oppenheimer assumed coverage on shares of Opus Genetics in a report on Monday, March 16th. They set an “outperform” rating and a $10.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $10.77.

Read Our Latest Research Report on Opus Genetics

Opus Genetics Stock Down 6.6%

Shares of NASDAQ IRD opened at $3.56 on Monday. The business’s 50 day moving average is $4.25 and its two-hundred day moving average is $3.95. Opus Genetics has a 52-week low of $1.04 and a 52-week high of $5.81. The firm has a market cap of $293.93 million, a price-to-earnings ratio of -2.68 and a beta of 0.55.

Opus Genetics (NASDAQ:IRD – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.59). Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 892.36%.The firm had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $2.93 million. Analysts anticipate that Opus Genetics will post -1.08 EPS for the current fiscal year.

Insider Activity at Opus Genetics

In other news, CFO Robert E. Gagnon sold 7,842 shares of the company’s stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $5.18, for a total transaction of $40,621.56. Following the completion of the transaction, the chief financial officer directly owned 592,158 shares of the company’s stock, valued at approximately $3,067,378.44. This represents a 1.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ashwath Jayagopal sold 7,542 shares of the stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $5.19, for a total value of $39,142.98. Following the completion of the transaction, the insider owned 509,233 shares in the company, valued at approximately $2,642,919.27. The trade was a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,738,703 shares of company stock worth $7,596,606 over the last three months. Company insiders own 11.70% of the company’s stock.

Hedge Funds Weigh In On Opus Genetics

Several hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in Opus Genetics during the fourth quarter worth approximately $34,000. Occudo Quantitative Strategies LP acquired a new position in shares of Opus Genetics in the 4th quarter valued at $25,000. ADAR1 Capital Management LLC purchased a new position in shares of Opus Genetics in the 4th quarter valued at $80,000. Blair William & Co. IL grew its position in shares of Opus Genetics by 12.3% in the 4th quarter. Blair William & Co. IL now owns 27,466 shares of the company’s stock valued at $55,000 after buying an additional 3,000 shares during the last quarter. Finally, Johnson Investment Counsel Inc. acquired a new stake in Opus Genetics during the 4th quarter worth $40,000. 14.97% of the stock is currently owned by hedge funds and other institutional investors.

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.